Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | anti-KRAS G12V mTCR cells |
Synonyms | |
Therapy Description |
Anti-KRAS G12V mTCR cells are peripheral blood lymphocytes engineered to express a murine T-cell receptor targeting KRAS G12V, potentially leading to inhibition of tumor growth (PMID: 26701267). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
anti-KRAS G12V mTCR cells | Anti-KRAS G12V mTCR cells are peripheral blood lymphocytes engineered to express a murine T-cell receptor targeting KRAS G12V, potentially leading to inhibition of tumor growth (PMID: 26701267). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03190941 | Phase Ib/II | Cyclophosphamide anti-KRAS G12V mTCR cells Fludarabine Aldesleukin | Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients | Recruiting | USA | 0 |